Windward Bio Secures $700M Licensing Deal for Dual-Target Bispecific Antibody WIN027
核心洞察
Windward Bio (搜索) announced a licensing agreement with Qyuns Therapeutics (搜索) for WIN027 (搜索), a bispecific antibody targeting TSLP (搜索) and IL-13 (搜索) with potential applications in asthma (搜索), COPD (搜索), and atopic dermatitis (搜索).
The deal is valued at up to $700 million including upfront payments, equity, milestones, and royalties, granting Windward exclusive rights outside of China.
WIN027 (搜索) is engineered for extended half-life and less frequent dosing, currently in Phase 1 development with subpicomolar affinity for both targets.
Windward Bio (搜索) AG has secured exclusive global rights to develop and commercialize WIN027 (搜索), a dual-targeting bispecific antibody, through a licensing agreement with Qyuns Therapeutics (搜索) valued at up to $700 million. The deal expands Windward's immunology pipeline with a therapy designed to address respiratory and dermatological diseases by simultaneously blocking TSLP (搜索) and IL-13 (搜索), two well-validated inflammatory drivers.
Novel Dual-Target Approach
WIN027 (搜索) represents a potential best-in-class humanized IgG1 bispecific monoclonal antibody with subpicomolar affinity for both TSLP (搜索) and IL-13 (搜索). The therapy has been engineered to extend half-life and enable less frequent dosing compared to existing biologics. Through this dual, long-acting inhibition mechanism, WIN027 is designed to deliver deeper and more durable disease control in conditions including asthma (搜索), chronic obstructive pulmonary disease (COPD (搜索)), and atopic dermatitis (搜索).
"We are excited to add WIN027 (搜索) to our growing pipeline of immunology therapies," said Luca Santarelli, MD, Founder, Chief Executive Officer, and Board Chair of Windward Bio (搜索). "Its high potency against TSLP (搜索) and IL-13 (搜索), as well as an extended dosing interval, has the potential to provide people with respiratory and dermatology diseases enhanced efficacy, greater convenience, and better control over their disease."
Strategic Pipeline Expansion
The licensing agreement marks Windward Bio (搜索)'s second major deal in 2025, underscoring the company's strategic focus on building a comprehensive immunology portfolio. WIN027 (搜索) complements the company's lead program WIN378, a long-acting anti-TSLP (搜索) monoclonal antibody currently in Phase 2 development. Together, these therapies address significant unmet medical needs across immunological diseases, representing a combined market opportunity exceeding $50 billion.
WIN378 is being evaluated in POLARIS, a global Phase 2 trial in asthma (搜索) patients, with initial data expected in 2026. The therapy has demonstrated extended half-life for prolonged dosing intervals, low antidrug antibody rates, and favorable safety profiles in Phase 1 studies. A Phase 2 study in COPD (搜索) is also planned to begin in 2026.
Deal Structure and Development Timeline
Under the licensing terms, Windward Bio (搜索) gains exclusive rights to develop, manufacture, and commercialize WIN027 (搜索) outside of China through its affiliate, LE2025 Therapeutics AG. The $700 million total deal value includes upfront payments, equity investments, and milestone payments contingent upon achieving specific development, regulatory, and commercial objectives, plus tiered royalties on future product sales.
WIN027 (搜索), also known as QX027N, is currently in Phase 1 development. Qyuns Therapeutics (搜索) retains rights in China, Hong Kong, Macao, and Taiwan. The bispecific antibody's engineered properties enable subcutaneous administration with extended dosing intervals, potentially improving patient compliance and treatment outcomes.
Market Positioning
Windward Bio (搜索) launched earlier this year with a $200 million Series A funding round led by top-tier investors. The company positions itself as a clinical-stage biotechnology firm with expertise in discovery, development, and commercialization of therapies for advanced immunological conditions. The addition of WIN027 (搜索) strengthens the company's pipeline of long-acting bispecific antibodies targeting validated biological pathways in respiratory and dermatological diseases.